Log In
BCIQ
Print this Print this
 

SER-262

  Manage Alerts
Collapse Summary General Information
Company Seres Therapeutics Inc.
DescriptionSynthetically derived microbiome consisting of 12 bacterial strains in spore form
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPhase I
Standard IndicationClostridium
Indication DetailsTreat Clostridium difficile infection (CDI)
Regulatory Designation
PartnerNestle S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,880.0M

$120.0M

$1,760.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/11/2016

$1,880.0M

$120.0M

$1,760.0M

Get a free BioCentury trial today